Adaptive Biotechnologies (ADPT) Debt to Equity (2022 - 2025)
Adaptive Biotechnologies (ADPT) has disclosed Debt to Equity for 4 consecutive years, with $0.6 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 8.89% to $0.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.6 through Dec 2025, down 8.89% year-over-year, with the annual reading at $0.6 for FY2025, 8.89% down from the prior year.
- Debt to Equity hit $0.6 in Q4 2025 for Adaptive Biotechnologies, down from $0.65 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.74 in Q2 2025 to a low of $0.27 in Q4 2022.
- Historically, Debt to Equity has averaged $0.55 across 4 years, with a median of $0.59 in 2024.
- Biggest five-year swings in Debt to Equity: soared 65.21% in 2024 and later decreased 8.89% in 2025.
- Year by year, Debt to Equity stood at $0.27 in 2022, then skyrocketed by 56.91% to $0.42 in 2023, then surged by 55.3% to $0.66 in 2024, then dropped by 8.89% to $0.6 in 2025.
- Business Quant data shows Debt to Equity for ADPT at $0.6 in Q4 2025, $0.65 in Q3 2025, and $0.74 in Q2 2025.